Combinations May Combat PARP Resistance

Video

Combining PARP inhibitors with another kind of agent may be key in overcoming resistance.

The implementation of PARP inhibitors is one of the most exciting additions to the treatment of gynecologic cancer, said Leslie M. Randall, MD, MAS, associate professor in the Division of Gynecologic Oncology at the University of California in Irvine.

However, many patients become resistant to the drugs and progress. Combinations, such as a PARP inhibitor plus an immunotherapy agent or PI3K inhibitor, are now being explored to overcome this resistance and lead to better outcomes.

Related Videos
Elizabeth Aronson
MPN-Associated Anemia: What Nurses Should Look Out For
Cancer-Related Cognitive Impairment
Charina Toste
Lindsey Lyle
Alyssa Ridad
Yelena Shames
Johanna Garibaldi
Related Content
© 2023 MJH Life Sciences

All rights reserved.